Literature DB >> 7874610

Clinical testing in diabetic peripheral neuropathy.

E L Feldman1, M J Stevens.   

Abstract

Diabetic polyneuropathy is a complex disease of progressive nerve fiber loss. Initial screening and diagnosis in clinical practice usually depend on assessment of subjective complaints. A need exists for objective, simple, and reproducible assessment tools that can be readily used in clinical practice. The importance of early diagnosis is highlighted by the recent North American Diabetes Control and Complications Trial where intensive insulin therapy reduced the risk of developing diabetic neuropathy by 61%. At the University of Michigan, we have developed an outpatient neuropathy program. Patients are given a questionnaire and a brief screening examination, designated the Neuropathy Screening Instrument. Diabetic neuropathy is confirmed and staged in patients with a positive Neuropathy Screening Instrument, by a quantitative neurologic examination and nerve conduction studies, designated the Diabetic Neuropathy Score. The Michigan program has been compared with well-established instruments and has been found to be sensitive and reproducible for screening and diagnosis. We believe the program provides a valuable tool for the clinician in the practice setting and should allow diagnosis and intervention earlier in the course of diabetic neuropathy.

Entities:  

Mesh:

Year:  1994        PMID: 7874610     DOI: 10.1017/s0317167100040671

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  25 in total

1.  A Phase II dose titration study of thalidomide for cancer-associated anorexia.

Authors:  Mellar Davis; Wael Lasheen; Declan Walsh; Fade Mahmoud; Leslie Bicanovsky; Ruth Lagman
Journal:  J Pain Symptom Manage       Date:  2011-06-02       Impact factor: 3.612

2.  Risk Factors For Diabetic Polyneuropathy.

Authors:  Yüksel Kaplan; Semiha Kurt; Hatice Karaer Ünaldi; Ünal Erkorkmaz
Journal:  Noro Psikiyatr Ars       Date:  2014-03-01       Impact factor: 1.339

3.  Racial differences in the association between self-rated health status and objective clinical measures among participants in the BARI 2D trial.

Authors:  Stephen B Thomas; Veronica V Sansing; Andrew Davis; Michelle Magee; Elaine Massaro; V S Srinivas; Tarek Helmy; Patrice Desvigne-Nickens; Maria Mori Brooks
Journal:  Am J Public Health       Date:  2010-02-10       Impact factor: 9.308

Review 4.  Diabetic neuropathy: cellular mechanisms as therapeutic targets.

Authors:  Andrea M Vincent; Brian C Callaghan; Andrea L Smith; Eva L Feldman
Journal:  Nat Rev Neurol       Date:  2011-09-13       Impact factor: 42.937

5.  To evaluate the efficacy of an acellular Flowable matrix in comparison with a wet dressing for the treatment of patients with diabetic foot ulcers: a randomized clinical trial.

Authors:  F Campitiello; M Mancone; A Della Corte; R Guerniero; S Canonico
Journal:  Updates Surg       Date:  2017-05-11

6.  Serial anthropometry predicts peripheral nerve dysfunction in a community cohort.

Authors:  Kelly R Ylitalo; William H Herman; Siobán D Harlow
Journal:  Diabetes Metab Res Rev       Date:  2013-02       Impact factor: 4.876

7.  Performance-based physical functioning and peripheral neuropathy in a population-based cohort of women at midlife.

Authors:  Kelly R Ylitalo; William H Herman; Siobán D Harlow
Journal:  Am J Epidemiol       Date:  2013-03-22       Impact factor: 4.897

Review 8.  Impact of Diabetic Complications on Balance and Falls: Contribution of the Vestibular System.

Authors:  Linda J D'Silva; James Lin; Hinrich Staecker; Susan L Whitney; Patricia M Kluding
Journal:  Phys Ther       Date:  2015-08-06

9.  Diagnostic accuracy of fall risk assessment tools in people with diabetic peripheral neuropathy.

Authors:  Stephen D Jernigan; Patricia S Pohl; Jonathan D Mahnken; Patricia M Kluding
Journal:  Phys Ther       Date:  2012-07-26

10.  Standing balance and trunk position sense in impaired glucose tolerance (IGT)-related peripheral neuropathy.

Authors:  Allon Goldberg; James William Russell; Neil Burton Alexander
Journal:  J Neurol Sci       Date:  2008-04-25       Impact factor: 3.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.